进展期胃癌抗HER2治疗研究进展  

Advances in anti-HER2 therapy in advanced gastric cancer

作　　者：张芮毫(综述) 张明(审校)[1] ZHANG Rui-hao;ZHANG Ming(Department of Oncology,Suzhou Hospital,Nanjing Medical University,Suzhou Cancer Diagnosis and Treatment Center,Suzhou City Hospital East,Suzhou 215000,Jiangsu,China)

机构地区：[1]南京医科大学附属苏州医院/苏州市肿瘤诊疗中心(苏州市立医院东区)肿瘤内科,苏州215000

出　　处：《医学研究生学报》2022年第2期218-224,共7页Journal of Medical Postgraduates

基　　金：苏州市科学技术基金(SLJ202011)

摘　　要：胃癌是一种全球性高致死性的恶性肿瘤,早期内镜下切除可使部分患者达到临床治愈的可能,但大部分患者出现症状就诊时已处于不可切除的进展期状态,全身性治疗是进展期患者首要的治疗方式。目前认为恶性肿瘤的发生发展是多基因调控的结果,因此在基因蛋白水平探索肿瘤生物特性、预后指标及发现治疗的新靶点是肿瘤研究的重点。近年来出现的数个抗人类表皮生长因子受体2(HER2)治疗的靶向药物,包括新型HER2人源化单克隆抗体、ADC、TKI抑制剂等。文章主要就近年来胃癌抗HER2治疗的重要临床试验,建立更完善的进展期胃癌临床治疗策略进行综述。Gastric cancer is a global malignant tumor with high mortality.Early endoscopic resection can make clinical cure possible for most patients,but most patients are already in the unresectable advanced stage when presenting symptoms.Systemic treatment is the primary treatment for patients with advanced stage.At present,it is considered that the occurrence and development of malignant tumors is the result of multi-gene regulation.Therefore,it is the focus of tumor research to explore tumor biological characteristics,prognostic indicators and find new therapeutic targets at gene protein level.Several targeted drugs against HER2 therapy have e-merged in recent years,including novel HER2 humanized monoclonal antibody,antigen-conjugated drugs,TKIs,etc.This paper introduces these drugs and their important clinical trials in recent years,hoping to help establish a more perfect clinical treatment strategy for advanced gastric cancer.

关 键 词：胃癌 靶向治疗 曲妥珠单抗 人类表皮生长因子受体2 

分 类 号：R735.2[医药卫生—肿瘤]